The first clinical evidence for in vivo gene editing, and a surge in valuation, is to be celebrated. But there is much more to do.
Casirivimab plus imdevimab could at last add a hospitalised Covid-19 patient treatment string to their bow.
But data are early, and other groups are also developing less frequent injections for wet AMD.
But AZD7442 still has two more bites at the cherry.
The long overdue advent of US cut-price oncology drugs is a major theme at this year’s Asco, and Junshi’s toripalimab leads the way.
With a Darpin antiviral for treating Covid-19 Molecular Partners hopes to follow Vir’s regulatory path.
The addition of Celgene made Bristol’s sales team pharma’s most productive last year on one measure, but the accolade might be short-lived.